Objective: The objective of this study is to assess nevirapine (NVP) resistance in infants who became infected in the three arms of the Breastfeeding, Antiretrovirals and Nutrition (BAN) study: daily infant NVP prophylaxis, triple maternal antiretrovirals or no extra intervention for 28 weeks of breastfeeding.
Introduction
There have been several clinical trials aimed at reducing transmission of HIV from infected mothers to their infants via breastfeeding using antiretroviral drugs as a treatment or prophylaxis. These trials have included an increased duration of infant nevirapine (NVP) prophylaxis from 6 weeks up to 6 months [1] [2] [3] , or antiretroviral drug for the mother for up to 6 months [4] [5] [6] . Longer infant prophylaxis or maternal antiretroviral drug resulted in reduced HIV transmission in these trials [7] . Resistance to antiretroviral drugs, either in mothers or in infants who become infected, may limit the effectiveness of prophylaxis and/or limit effective treatment regimens in mothers and infants who do became infected with HIV.
The Breastfeeding, Antiretrovirals and Nutrition (BAN) study was a randomized trial occurring between 2004 and 2010 in Lilongwe, Malawi, comparing three strategies during 28 weeks of breastfeeding: antiretroviral drugs given to breastfeeding mothers with CD4 þ lymphocyte counts more than 200 cells/ml, daily NVP prophylaxis for the infant and no intervention (control, which was standardof-care at the time). Mothers were advised to wean between 24 and 28 weeks, interventions were stopped at 28 weeks, and both mothers and infants were scheduled to be followed for an additional 20 weeks. Both interventions were effective in reducing the risk of HIV transmission during breastfeeding (1.7% infected in infant-NVP arm and 2.9% in maternal-antiretroviral drug arm, vs. 5.7% in the control arm) [8] . During the follow-up period, an additional 28 infants became infected [9] . Antiretroviral-resistant HIV in the mother is a possible risk factor for NVP resistance (NVP R ) virus in the HIVinfected infants in all three BAN arms. SdNVP was given to all of the mothers in the BAN study to prevent transmission during delivery, and NVP R commonly occurs after a single dose [10] , although mothers in the BAN study were also given a week of zidovudine (ZDV)/ lamivudine (3TC) treatment after delivery to reduce the development of maternal NVP R [11] . Mothers in the maternal-antiretroviral arm could also develop resistant HIV with a poor adherence to their regimen. If the mothers had resistant virus prior to transmission via breastfeeding, the infants should have the same resistance mutations in their HIV as found in their mothers. The objectives of this study were to determine whether the infants in the intervention arms had more frequent detection of NVP R or other reverse transcriptase mutations over the control arm and compare resistance mutations between infants and mothers.
Materials and methods

Study participants
Mother-infant pairs were enrolled in the BAN study with informed consent. The trial was approved by the Malawi National Health Science Research Committee and by the institutional review boards at the University of North Carolina at Chapel Hill and the U.S. Centers for Disease Control and Prevention (CDC). At the time of delivery, all mothers and infants were given single-dose NVP (sdNVP) and 1 week of ZDV/3TC to reduce NVP R [11] . After delivery, mother-infant pairs were randomized to one of three arms: the maternalantiretroviral arm in which the mother received antiretroviral drug therapy (ZDV/3TC/NVP, ZDV/ 3TC/nelfinivir or ZDV/3TC/ritonavir-boosted lopinavir) for 28 weeks, the infant-NVP arm in which the infant received daily NVP prophylaxis for 28 weeks or the control arm in which neither the mother nor the child received additional antiretroviral [12] . Only the first few mothers randomized to the maternal-antiretroviral arm received NVP in their antiretroviral drug regimen before NVP was replaced with other drugs. Infants were tested for HIV infection at birth and at 2, 12, 28 and 48 weeks of age [Roche Amplicor DNA Assay, v1.5 (Roche Molecular Diagnostics, Indianapolis, Indiana, USA) on whole blood pellets]. Positive tests were confirmed with a Roche DNA test on a follow-up blood sample. Motherinfant pairs in which the infant tested HIV-positive at birth or 2 weeks were removed from the cohort. Retrospective testing was performed on dried blood spots (DBS) (collected at 4, 8 10, 16, 20, 24 and 36 weeks) from the HIV-positive infants to narrow the window of infection [8, 9] . The days from birth to HIV infection were estimated as the midpoint between the date of the last specimen that tested negative and the date of the first specimen that tested positive. The days on NVP prophylaxis were calculated for each infant from the date of birth to the either the documented cessation of NVP or the first visit date after their first HIV-positive screen date, when the infant would have had its positive test confirmed and the mother would have been told to stop NVP prophylaxis. The number of days on NVP while HIV-positive were estimated as the difference between the number of days on NVP and the number of days from birth to HIV infection.
Specimens
The latest available infant plasma or DBS after the infant became HIV-positive was used for sequencing (median interval between first positive test and sequencing of 85 days; range 0-378 days). Infant plasma was unavailable at many visits due to missed visits [13] or insufficient blood volume drawn. Some of the DBS could not be amplified. Therefore, there were large gaps between the first positive visit and the visit that was sequenced for most of the infants. Breastmilk was collected from mothers starting at delivery and continuing every 2-6 weeks until weaning by 28 weeks; maternal plasma was collected at screening during pregnancy, at delivery and every 2-6 weeks until 48 weeks postdelivery. Maternal plasma from the closest time point to transmission was used for sequencing when available (19 from same visit as the infant tested positive, eight from 2-6 weeks before, two from 4 weeks after and one each from 12 weeks after, 12 weeks before and 18 weeks before; samples were not available from all mothers). In one case, only breastmilk from the time of transmission was available (same visit) and was used for sequencing.
Sequencing
HIV-1 RNA was isolated either from plasma using a Qiagen Viral RNA Mini Kit (Qiagen, Inc., Valencia, California, USA), or from DBS or whole breastmilk using the Abbott RNA Sample Prep on the m2000sp (Abbott Molecular, Des Plaines, Illinois, USA). HIV-1 RNA was reverse transcribed, amplified and sequenced as described previously [11] . Amplification was unsuccessful for some specimens; alternate samples were sought in these cases, including DBS. The complete RT region of interest (approximately the first two-thirds of the gene in which the RT inhibitor mutations are found) [11] could not be amplified from DBS-derived RNA, so alternate primers were designed to amplify two smaller amplicons that encompassed the NVP resistance mutations. The first set was for a 419 bp amplicon (first round primers KCRTUP1 (5 0 -TGGGCCTGAAAATCC-3 0 ) and KCRTDN1 (5 0 -GCTCTATGTTGCCCTATTTCTAA GTC-3 0 ); second round primers KCRTUP2 (5 0 -CCA TATAACACTCCAGTATTTGC-3 0 ) and KCRTDN2 (5 0 -TCTAAGTCAGATCCTACATACAAGTC-3 0 )). The second set was for a 312 bp amplicon [first round primers KCRTUP3 (5 0 -GAACTCAAGACTTTTGG GAAGTTC-3 0 ) and KCRTDN1; second round primers KCRTUP4 (5 0 -TCAATTAGGAATACCACACCC-3 0 ) and KCRTDN2]. These alternate primers were used on the DBS RNA to get the longest amplicon possible. Sequences were aligned and phylogenetic trees were made with CLC Sequence Viewer (CLC bio A/S) to ensure linkage between maternal and infant sequences in a mother-infant pair with no cross-contamination between any samples. Sequences have been submitted to GenBank under accession numbers KP981253-KP981362.
Statistical analyses
Associations between the presence of NVP resistance in infants and each predictor were assessed using Fisher's exact test for binary variables and the Wilcoxon rank-sum test for continuous variables. P values less than 0.05 were considered statistically significant; no adjustments were made for multiple testing.
Results
Of the 93 infants infected with HIV in the BAN study between 3 and 48 weeks of age, unique RT sequences were generated from 78. Infants in the infant-NVP arm were significantly more likely to have NVP R mutations (41%) than infants in the other two trial arms (4% in the maternal-antiretroviral arm and 9% in the control arm, P ¼ 0.001; Table 1 ). For infants infected between 3 and 28 weeks, the frequency of NVP R was 56% among nine sequenced HIV-infected infants in the infant-NVP arm compared with significantly smaller percentages of NVP R in the HIV-infected infants in the other arms (6% of 16 sequenced infected infants in the maternal-antiretroviral arm and 11% of 28 sequenced infected infants in the control arm, P ¼ 0.004; Table 1 ). After the antiretroviral interventions stopped at 28 weeks, infants who became HIV-infected in the infant-NVP arm still had a high frequency of NVP R (31%), with no resistance in infected infants from the other two arms ( Table 1) .
Retrospective testing of the infants who first tested positive for HIV after 2 weeks of age revealed that among 86 infants with no loss to follow-up, 24 (28%) infants had their first HIV-positive specimen when they were diagnosed (no delay). The other infants had delays between their first HIV-positive specimen from retrospective testing and actual diagnosis, and thus had continued exposure to prophylactic/subtherapeutic levels of NVP until diagnosis was confirmed: 26 (30%) infants had up to a 6-week delay, 30 (35%) had up to a 12-week delay, five (6%) had a 15-17 week delay and one (1%) had a 27-week delay (an extended time period between the postweaning visit at 28 weeks and the final visit at 48 weeks). Among infants in the infant-NVP arm who were infected from 3 to 28 weeks, infants with NVP R HIV tended to test HIV-positive earlier [median 108.5 days of age with NVP R vs. 166.0 days with NVP-sensitive Nevirapine resistance in infants on prophylaxis Nelson et al. 2133 (NVP S )], and to thus have longer exposure to prophylactic NVP after becoming infected (median 76.5 days) than infants with NVP S HIV (median 25.0 days), although neither of these differences were statistically significant ( Table 2 ). Other potential predictors of NVP R in infected infants were examined by univariate analyses. Sex, birth weight, predelivery maternal CD4 þ cell count and predelivery maternal viral load were not statistically significantly associated with NVP R in the infected infants, either in the infant arm alone or among all of the infected infants sequenced (data not shown).
To determine whether the infants with NVP R acquired resistant HIV from their mothers, we sequenced the RT genes from maternal plasma (and in one case breastmilk) as close to the time of transmission as samples were available (Fig. 1 ). For the nine infants with NVP R in the infant-NVP arm, four of the mothers had no NVP R mutations, three mothers had the same NVP R mutation as their infants and two mothers had different NVP R mutations from their infants ( Table 3) . Limited resistance was seen in mothers in the other two arms of the trial whose infants had NVP R or other RT resistance mutations, although we did not sequence many of the mothers because there were few cases of resistance in the infants. Of note, none of the few mothers in the maternal arm who were taking an NVPcontaining regimen transmitted HIV to their infants. The transmitting mothers in the maternal-antiretroviral arm had detectable virus in plasma and/or breast milk at most time points tested, so nonadherence was likely in these mothers (Davis et al., in preparation). The mother of the only infant with NVP R in the maternalantiretroviral arm did not have any resistance mutations; this infant had two NVP R mutations and one 3TC resistance mutation. Of the three mothers in the control arm whose infants had NVP R , one mother had no NVP R mutations, one mother had the same NVP R mutation as her infant mixed with the wild type and one mother had the complicated situation of having one NVP R mutation shared with her infant, one unique NVP R mutation and missing the 3TC resistance mutation that her infant had (mother-infant pairs 46-48, respectively; Table 3 ).
2134 AIDS 2015, Vol 29 No 16 Fig. 1 . Details on infected infants and mothers in the BAN study whose HIV reverse transcriptase gene was sequenced. Samples were unavailable or sequencing was unsuccessful for 15 of the infected infants; there was no statistically significant difference between infected infants with and without sequence in terms of study arm or number of days until first HIV-positive test.
Maternal plasma was also sequenced for the rest of the HIV-infected infants in the infant-NVP arm (all 13 mothers had plasma available) and five of the HIVinfected infants in the maternal-antiretroviral arm to determine whether mothers of infants with NVP S HIV had any resistance mutations that were not transmitted ( Table 3) . Among these mothers, one (7.7% in the infant-NVP arm) carried an NVP R mutation that her infant did not have (mother-infant pair 13, Table 3 ). The maternal sample was from 20 weeks, while her infant first tested HIV-positive at 29 weeks.
In the control arm of the BAN study, 38 of 668 (5.7%) infants were observed to become infected between 3 and 48 weeks of age, whereas in the infant-NVP arm, 25 of 852 (2.9%) infants were observed to become infected at 3-48 weeks of age. Therefore, we can estimate that approximately 24 more HIV infections would have been observed had, contrary to fact, these infants not been assigned NVP prophylaxis. Of the infants in the infant-NVP arm who had their specimens sequenced in this study, 40.9% had NVP resistance mutations. In contrast, only 9.1% of the infants in the control arm who were sequenced had NVP resistance mutations. Assuming that infected infants in the infant-NVP arm would still have been infected if they had not received NVP prophylaxis, we estimate that approximately eight of the 25 infected infants (32%) in the infant-NVP arm had resistance attributable to NVP prophylaxis. The rest of the observed NVP R would presumably be due to NVP exposure at birth, the same as in the control and maternalantiretroviral arms.
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Discussion
Mother-to-child transmission of HIV via breastfeeding is preventable by giving the infant NVP prophylactically and/or treating the mother with antiretroviral therapy to suppress viral replication. In the BAN study, in which these two interventions were compared with a control arm that received neither intervention, NVP prophylaxis during breastfeeding decreased the risk of HIV transmission with approximately 24 infections averted among 852 infants in the infant-NVP arm [8] . However, 56% of the infants who became infected while receiving NVP prophylaxis had NVP R , which was significantly more than observed in infants in the other arms of the BAN study. Other studies of infant NVP prophylaxis during breastfeeding have found even higher rates of NVP R among infants infected while taking prophylaxis [92% of infants who became positive between 1 and 6 weeks of age in the SWEN study (which used NVP prophylactically for 6 weeks), 83% in the PEPI-Malawi study (NVP prophylaxis given for 14 weeks) and 75% in the HPTN046 Study (NVP prophylaxis given for 6 months)] [14] [15] [16] . The lower rate in BAN may be due to fewer mothers developing NVP R after single-dose peripartum NVP [11] , as all of the mothers (and infants) in BAN received a week of ZDV/3TC specifically to reduce NVP R . Alternatively, the lower rate observed in BAN may be due to chance; the small numbers of infections in the infant NVP arm preclude precise inference about the rate of NVP R in BAN. Only three of nine infants with NVP R in the infant-NVP arm had the same resistance patterns as their mothers, suggesting that one in three infants with NVP R received a resistant strain from their mothers and the rest were initially infected with NVP S virus that subsequently became resistant in the infant. This is in agreement with data from the SWEN study [14] .
We found a nonsignificant trend suggesting that infants with NVP R tended to have longer exposure to NVP while infected than did infants without NVP R . Testing the infants more often would prevent this problem, but that would require additional costs for visits and testing, adding to the strain of very busy clinics and laboratories in resource-limited settings. Our results also emphasize the importance of having treatment regimens available for these infants that exclude the drug used for prophylaxis.
We observed an increased proportion of NVP R in the infant-NVP arm, compared with the maternal-antiretroviral and control arms, among infants infected between 29 and 48 weeks, after the prophylactic interventions had ended. The observed prevalence of NVP R in the infant-NVP arm (31%) in this timeframe was higher than the 15% NVP R among infants who became infected after the 6 weeks of extended NVP in the SWEN study [14] . Mothers in the SWEN study continued breastfeeding after the 6 weeks of prophylaxis for their infants, contrary to the BAN study in which mothers were advised to stop at 28 weeks postpartum. Although there was a fraction of BAN mothers who did not wean by 28 weeks [9] , more extensive testing of some of the late infections in BAN with very sensitive assays indicated that at least some of these 'late' infections occurred prior to 28 weeks, but were not detected by the in-country test until after 28 weeks [17] ( Table 3 ). The rates of resistance in the BAN and SWEN studies may be more similar if many of the late infection infants with NVP R were actually infected while they were taking NVP prophylaxis, but we lack the specimens to more accurately date the time of infection for all of the 'late' infections. Nevertheless, the HIV transmissions after 28 weeks point to the importance of continuing prophylaxis until breastfeeding has completely stopped.
Differences in resistance mutations between mothers and infants in the majority of cases of infant NVP resistance indicate that many infants acquired a resistance mutation after transmission of NVP S virus from the mothers due to subtherapeutic NVP dosing. In addition, we saw potential evidence that the presence of maternal NVP R does not mean that NVP prophylaxis will fail: the infants born to three NVP R mothers did not test HIV positive until well after the prophylaxis was stopped (mother-infant pairs 6, 7 and 9, Table 3 ), implying the infants were protected while they took the NVP. However, more sensitive testing [17] found that one of these three infants (9) actually became HIV-positive before stopping NVP prophylaxis, so it may be that the other two mothers transmitted earlier, but we do not have the specimens for more sensitive testing.
Only two of the 23 infected infants with sequence data in the maternal-antiretroviral arm had resistance to any RT inhibitors (one to NVP and ZDV, the other to 3TC; Table  3 ) despite the mothers being treated with two or three RT inhibitors. In the Kisumu Breastfeeding Study in which mothers were given antiretroviral drugs during 6 months of breastfeeding, 67% of infected infants had any resistance at 6 months [16] , while in the current study, we found that only two of 16 infected infants by 28 weeks (12.5%) had any resistance to NVP or ZDV/3TC. Even though we only sequenced virus from the mother of the one infant in the maternal-antiretroviral arm with NVP R along with six randomly selected mothers of infected infants in that arm, the lack of resistance in the infants implies that infants became infected for reasons other than resistance in the mothers. Among mother-infant pairs in the control arm, we did find instances of resistance to NVP and other RT inhibitors (two out of three mothers sequenced and three out of 33 infants sequenced). Of note, all of the infants with NVP R in the maternalantiretroviral and control arms had tested HIV-positive by 6 weeks of age, making it likely that the sdNVP and week of ZDV/3TC given after delivery to mothers and infants led to the resistance in these infants. A previous study of BAN and non-BAN mothers showed that addition of a week of ZDV/3TC to the sdNVP at delivery prevented most, but not all, NVP R in the mothers [11] , so the few cases we observed could be attributed to the low level of NVP R in spite of ZDV/3TC use.
Limitations of this trial included the small number of infections and missing samples for some of the infants and mothers, both of which decrease our effective sample size, and the temporal gap between collection of maternal and infant samples and actual time of transmission. The temporal gap may affect our calculations of time on NVP while HIV-positive and how well the sequences we found in the mother represent the viruses that may have been transmitted by the mother. The analysis examining the association between NVP R and duration of NVP exposure after infection was based only on 10 infants and therefore had low statistical power ( Table 2) . Another limitation was the use of population sequencing to look for resistance in the mothers and infants. Comparison of mother and infant sequences confirmed transmission and ruled out contamination of the samples, but transmission of a resistant variant when both mother and infant have the same mutation cannot be confirmed by these methods. Mixtures of NVP S and NVP R virus were seen in three mothers whose infants did not have the same resistance mutations (mother-infant pairs 7, 13 and 48, Table 3 ) and in two mothers whose infants had the same resistance mutation (pairs 6 and 46, Table 3 ).
Our data indicate that infants given NVP prophylaxis are largely protected from HIV infection during breastfeeding, but among those infants who become infected, they are at an increased risk of developing NVP R , especially if HIV testing is infrequent. These infected infants will need access to antiretroviral regimens that exclude NVP. Our results highlight the importance of early infant diagnosis of HIV for infants exposed via breastfeeding, with repeated testing necessary to identify and treat infected infants.
